Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Mar 14;40(3):238-240.
doi: 10.1016/j.ccell.2022.02.009. Epub 2022 Mar 3.

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Shun Yamamoto  1 , Ken Kato  2
Affiliations
Free article
Comment

JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma

Shun Yamamoto et al. Cancer Cell. .
Free article

Abstract

The phase III JUPITER-6 trial showed superior progression-free survival and overall survival for toripalimab plus chemotherapy, compared with chemotherapy alone, in previously untreated patients with advanced esophageal squamous cell carcinoma. This provides solid evidence that immune checkpoint inhibitors are key drugs for the first-line treatment of advanced esophageal squamous cell carcinoma.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Shun Yamamoto declares no competing interests. Ken Kato reports consulting fees from Bristol Myers Squibb, Merck Sharp & Dohme, Beigene, Roche, AstraZeneca, and Bayer; honoraria from ONO Pharmaceuticals, BMS, and Taiho; and research funding from ONO Pharmaceuticals, Bristol Myers Squibb, Merck Sharp & Dohme, Beigene, Chugai, Shionogi, AstraZeneca, and BAYER for research subjects outside the submitted work.

Comment on

  • Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
    Wang ZX, Cui C, Yao J, Zhang Y, Li M, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H, Cang S, Jiang Y, Wang J, Ye M, Chen Z, Jiang D, Lin Q, Ren W, Wang J, Wu L, Xu Y, Miao Z, Sun M, Xie C, Liu Y, Wang Q, Zhao L, Li Q, Huang C, Jiang K, Yang K, Li D, Liu Y, Zhu Z, Chen R, Jia L, Li W, Liao W, Liu HX, Ma D, Ma J, Qin Y, Shi Z, Wei Q, Xiao K, Zhang Y, Zhang Y, Chen X, Dai G, He J, Li J, Li G, Liu Y, Liu Z, Yuan X, Zhang J, Fu Z, He Y, Ju F, Liu Z, Tang P, Wang T, Wang W, Zhang J, Luo X, Tang X, May R, Feng H, Yao S, Keegan P, Xu RH, Wang F. Wang ZX, et al. Cancer Cell. 2022 Mar 14;40(3):277-288.e3. doi: 10.1016/j.ccell.2022.02.007. Epub 2022 Mar 3. Cancer Cell. 2022. PMID: 35245446 Clinical Trial.

MeSH terms

LinkOut - more resources